Compare BCC & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCC | NUVB |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.9B |
| IPO Year | 2013 | N/A |
| Metric | BCC | NUVB |
|---|---|---|
| Price | $85.61 | $5.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $101.83 | $10.44 |
| AVG Volume (30 Days) | 388.5K | ★ 6.3M |
| Earning Date | 02-19-2026 | 03-05-2026 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.07 | N/A |
| Revenue | ★ $6,511,894,000.00 | $26,748,000.00 |
| Revenue This Year | N/A | $616.63 |
| Revenue Next Year | $3.73 | $202.59 |
| P/E Ratio | $17.02 | ★ N/A |
| Revenue Growth | N/A | ★ 1137.19 |
| 52 Week Low | $65.14 | $1.54 |
| 52 Week High | $131.27 | $9.75 |
| Indicator | BCC | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 69.40 | 27.65 |
| Support Level | $72.86 | $6.07 |
| Resistance Level | $87.16 | $6.63 |
| Average True Range (ATR) | 2.95 | 0.53 |
| MACD | 1.06 | -0.42 |
| Stochastic Oscillator | 89.24 | 1.79 |
Boise Cascade Co is a producer of engineered wood products (EWP) and plywood. The firm operates in two reportable segments, namely Wood Products and Building Materials Distribution. The Wood Products segment manufactures laminated veneer lumber (LVL), I-joists, and laminated beams. In addition, it manufactures structural, appearance, and industrial-grade plywood panels, and ponderosa pine lumber. The Building Materials Distribution segment is engaged in the distribution of various building materials, including oriented strand board (OSB), plywood, and lumber; general line items such as siding, composite decking, doors and millwork, metal products, roofing, and insulation; and EWP, among others. The company generates a majority of its revenue from the Building Material Distribution segment.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.